Malodorous Infected Cutaneous Ulcer Clinical Trial
Official title:
An Open, Uncontrolled Study Investigating the Safety and Efficacy of GK567 in the Deodorization of Malodorous Infected Cutaneous Fungating Neoplastic Tumours, Over 14 Days of Treatment
This clinical trial objective is to investigate the safety and efficacy of GK567 to
alleviate malodour of foul smelling, anaerobically infected fungating neoplastic tumours,
over 14 days of treatment.
The clinical hypothesis is that the success rate is no worse than 70% in the population of
interest, where success for a patient is defined as a smell score of 0 or 1 at Day 14/end of
treatment, as assessed by the Study Investigator.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment